A prospective multicenter trial has been commenced in Korea to investigate the treatment efficacy of the levonorgestrel-releasing intrauterine system in patients with endometrial hyperplasia. The levonorgestrel-releasing intrauterine system is an alternative to oral progesterone without the disadvantages of oral progestogens. Therefore, we hypothesize that if the therapeutic efficacy of the levonorgestrel-releasing intrauterine system is similar to or greater than that of oral progesterone, the levonorgestrel-releasing intrauterine system could become the standard treatment for endometrial hyperplasia patients who do not want a hysterectomy. The levonorgestrel-releasing intrauterine system is inserted into uteri of patients with histologically confirmed endometrial hyperplasia. An office endometrial aspiration biopsy and transvaginal ultrasound are conducted every 3 months at an outpatients clinic. The primary endpoint is the response rate. The secondary endpoint is to estimate the consistency of the results of the office endometrial aspiration biopsy during the levonorgestrel-releasing intrauterine system being placed in uterus and a dilatation and curettage procedure.
INTRODUCTION
Endometrial hyperplasia (EH) is a known precursor of endometrial cancer. In women presenting with atypical hyperplasia, the risk of developing endometrial carcinoma is estimated to be 30% (1) . Consequently, hysterectomy has been the major treatment in the patients who do not want to become pregnant, especially in patients with atypical EH.
Oral progesterone products have been used as an alternative option in young women who wish to become pregnant. However, oral progesterone products are associated with poor compliance and systemic adverse effects such as headache, nausea, weight gain and thromboembolic events, which may limit the overall efficacy of the drugs. Moreover, the type of progestin product, the optimal dose and the duration of treatment are not clearly established (2) .
The levonorgestrel-releasing intrauterine system (LNG-IUS) is an alternative to oral progesterone without its disadvantages. Local-acting progesterone has an effect on the endometrium several times stronger than that exerted by systemic products and with less systemic effect. Therefore, the dose of progesterone can be reduced and the adverse reactions minimized. If the therapeutic efficacy of the LNG-IUS is similar to or greater than that of oral progesterone, the LNG-IUS could become the standard treatment for EH.
The effects of the LNG-IUS have been demonstrated in several observational studies (3, 4) , and in a systematic review (5) that included some limited studies (6 -10), but no large-scale prospective study has been undertaken.
Therefore, we designed a larger multicenter prospective study to evaluate the effectiveness of the LNG-IUS in the treatment of EH. 
PROTOCOL OF THE STUDY

ENDPOINTS
The primary endpoints of the study is the response rate. The secondary endpoint is to estimate the consistency of the results of the office endometrial aspiration biopsy during the LNG-IUS being placed in uterus and a dilatation and curettage (D&C) procedure.
STUDY SETTING AND PROTOCOL REVIEW
This study is a single-arm, prospective multi-institutional study. The protocol has been approved by the institutional review board (IRB) of each institution participating in the clinical trial.
PLANNED CLINICAL TRIAL PERIOD
Patient selection and enrollment: 12 months after IRB approval of the clinical trial is obtained.
TREATMENT METHODS
The LNG-IUS is inserted into the uteri of patients with histologically confirmed EH. An office endometrial aspiration biopsy and transvaginal ultrasound will be conducted, with the LNG-IUS inside the uterus, every 3 months at an outpatient clinic.
When the LNG-IUS has been inserted for a year, an endometrial aspiration biopsy will be performed with the LNG-IUS inside the uterus, and then D&C will be performed under anesthesia after LNG-IUS removal. The histologic diagnosis of all specimens will be made by central pathologic review. (All the samples were reviewed two independent gynecological pathologists.) The biopsy findings will be compared. If the office endometrial aspiration biopsy shows exacerbation of the hyperplasia (from EH without atypia to with atypia or from EH with atypia to carcinoma), treatment with the LNG-IUS will be stopped and another specific treatment initiated. 
PLANNED NUMBER OF SUBJECTS
Eighty patients with biopsy-proven EH (54 patients without atypical hyperplasia and 26 patients with atypical hyperplasia).
STATISTICAL CONSIDERATIONS
The primary objective of this study is to estimate the treatment efficacy of the LNG-IUS in patients with EH in terms of their response rates. We expect different response rate depending on the atypia status. The atypia status will be determined with an office endometrial aspiration biopsy, which will be performed before and 3 months after the LNG-IUS is inserted. The expected response rate is 70% for those with atypia and 85% for those without atypia. Different estimation approaches will be used according to the atypia status of the patients. For those patients without atypia, the response rate will be estimated with a margin of error of 10%. The sample size required for this estimate is 54 patients, after allowing for a 10% loss to follow-up. We
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Management of endometrial hyperplasia will compare patients with atypia in whom the expected response rate is 40%, with a historical control. The sample size required for this comparison is 26 patients to achieve 90% power and a 5% one-sided type I error, and 10% loss to follow-up. A response rate with a 95% confidence interval will be generated and the Z-test will be used to compare the response rates. The secondary objective is to estimate the consistency of the office endometrial aspiration biopsy during the LNG-IUS being placed in uterus and D&C results. Kappa statistics will be used
